Skip to main content
. Author manuscript; available in PMC: 2012 Jul 1.
Published in final edited form as: J Immunol. 2011 Jun 3;187(1):118–125. doi: 10.4049/jimmunol.1003378

FIGURE 6.

FIGURE 6

HMGB1 KD attenuates the ability of tumor cells to in vivo induce Treg. A, BALB/c-Foxp3-eGFP mice (3/group) were inoculated with 4T1.2-Neu WT, HMGB1 KD or KD control. After 2 weeks, Treg (eGFP+) in TDLN and spleen were measured by flow cytometry. Absolute numbers of Treg per spleen and TDLN are presented. Data are represented as mean ± SEM and combined from three independent experiments. HMGB1 KD vs. WT or KD control: p<0.05, WT vs. KD control: NS. B, Treg purified from 4T1.2-Neu WT, HMGB1 KD or KD control-inoculating mice were cocultured with CD4 and DC. HMGB1 KD vs. WT or KD control: p<0.05, WT vs. KD control: NS. The in vitro (C) and in vivo (D) suppressive activity of Treg from 4T1.2-Neu WT, HMGB1 KD or KD control-inoculating mice were measured as described in Fig.2A-B. Data (B-D) are represented as mean ± SEM. Results are combined from three (B-C) or two (D) independent experiments with at least one to two mice per group in each experiment. HMGB1 KD vs. WT or KD control: p<0.05, WT vs. KD control: NS.